Literature DB >> 15824420

Immunogenicity of mycobacterial PPE44 (Rv2770c) in Mycobacterium bovis BCG-infected mice.

Daniela Bonanni1, Laura Rindi1, Nicoletta Lari1, Carlo Garzelli1.   

Abstract

The Pro-Pro-Glu (PPE) protein family of Mycobacterium tuberculosis includes 69 glycine-rich proteins with a conserved N-terminal domain. Their role in tuberculosis is unknown, but it has been speculated that they may have an important immunological significance. In this investigation, the immunogenicity of the ppe44 (Rv2770c) gene product in BALB/c mice infected subcutaneously or intravenously with Mycobacterium bovis bacille Calmette-Guerin (BCG) was evaluated. Mice infected subcutaneously developed high titres of anti-PPE44 IgG1 antibodies, while PPE44-specific IgG2a antibodies were absent at all times tested. PPE44-primed cells from draining lymph nodes and spleen produced low levels of IFN-gamma, and a moderate degree of delayed-type hypersensitivity was observed following PPE44 intracutaneous challenge. In mice infected intravenously, the anti-PPE44 IgG1 antibody response was markedly higher compared with the subcutaneous infection; anti-PPE44 IgG2a antibodies at titres approximately 0.5-2.0 log(10) lower than IgG1 were detected. Interferon (IFN)-gamma production in PPE44-stimulated spleen-cell cultures was transient. These results indicate that PPE44 represents a novel mycobacterial antigen expressed during subcutaneous and intravenous infection by M. bovis BCG in BALB/c mice. Both infection models seem to polarize the immune response to PPE44 towards a Th2 phenotype, as testified by the IgG1 isotype being predominant over IgG2a and by the low IFN-gamma and delayed-type hypersensitivity responses.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15824420     DOI: 10.1099/jmm.0.45960-0

Source DB:  PubMed          Journal:  J Med Microbiol        ISSN: 0022-2615            Impact factor:   2.472


  14 in total

1.  Immunological Assessment of Chitosan or Trimethyl Chitosan-Coated PLGA Nanospheres Containing Fusion Antigen as the Novel Vaccine Candidates Against Tuberculosis.

Authors:  Sirwan Zare; Mona Kabiri; Yousef Amini; Adel Najafi; Fatemeh Mohammadpour; Seyed Hasan Ayati; Amin Reza Nikpoor; Mohsen Tafaghodi
Journal:  AAPS PharmSciTech       Date:  2021-12-10       Impact factor: 3.246

Review 2.  Evaluating the Performance of PPE44, HSPX, ESAT-6 and CFP-10 Factors in Tuberculosis Subunit Vaccines.

Authors:  Azar Valizadeh; Abbas Ali Imani Fooladi; Hamid Sedighian; Mahdieh Mahboobi; Elaheh Gholami Parizad; Elham Behzadi; Afra Khosravi
Journal:  Curr Microbiol       Date:  2022-07-19       Impact factor: 2.343

3.  Polymorphic exact tandem repeat A (PETRA): a newly defined lineage of mycobacterium tuberculosis in israel originating predominantly in Sub-Saharan Africa.

Authors:  Paul J Freidlin; Drora Goldblatt; Hasia Kaidar-Shwartz; Efrat Rorman
Journal:  J Clin Microbiol       Date:  2009-10-21       Impact factor: 5.948

4.  The transcriptional regulator Rv0485 modulates the expression of a pe and ppe gene pair and is required for Mycobacterium tuberculosis virulence.

Authors:  Rachael M Goldstone; Sunali D Goonesekera; Barry R Bloom; Samantha L Sampson
Journal:  Infect Immun       Date:  2009-08-03       Impact factor: 3.441

5.  Comparative analysis of Mycobacterium tuberculosis pe and ppe genes reveals high sequence variation and an apparent absence of selective constraints.

Authors:  Christopher R E McEvoy; Ruben Cloete; Borna Müller; Anita C Schürch; Paul D van Helden; Sebastien Gagneux; Robin M Warren; Nicolaas C Gey van Pittius
Journal:  PLoS One       Date:  2012-04-04       Impact factor: 3.240

6.  Identification of a human immunodominant T-cell epitope of mycobacterium tuberculosis antigen PPE44.

Authors:  Barbara Cuccu; Giulia Freer; Alessandro Genovesi; Carlo Garzelli; Laura Rindi
Journal:  BMC Microbiol       Date:  2011-07-25       Impact factor: 3.605

7.  Investigation of Immune Biomarkers Using Subcutaneous Model of M. tuberculosis Infection in BALB/c Mice: A Preliminary Report.

Authors:  Aliabbas A Husain; Hatim F Daginawala; Shubangi R Warke; Devanand R Kalorey; Nitin V Kurkure; Hemant J Purohit; Girdhar M Taori; Rajpal S Kashyap
Journal:  Immune Netw       Date:  2015-04-23       Impact factor: 6.303

8.  Increasing Cellular Immune Response in Liposomal Formulations of DOTAP Encapsulated by Fusion Protein Hspx, PPE44, And Esxv, as a Potential Tuberculosis Vaccine Candidate.

Authors:  Davood Mansury; Kiarash Ghazvini; Saeid Amel Jamehdar; Ali Badiee; Mohsen Tafaghodi; Amin Reza Nikpoor; Yousef Amini; Mahmoud Reza Jaafari
Journal:  Rep Biochem Mol Biol       Date:  2019-01

9.  Heterologous Expression, Purification, and Characterization of the HspX, Ppe44, and EsxV Proteins of Mycobacterium tuberculosis.

Authors:  Yousef Amini; Mohsen Tafaghodi; Saeid Amel Jamehdar; Zahra Meshkat; Bagher Moradi; Mojtaba Sankian
Journal:  Rep Biochem Mol Biol       Date:  2018-04

10.  Increasing the Vaccine Potential of Live M. bovis BCG by Coadministration with Plasmid DNA Encoding a Tuberculosis Prototype Antigen.

Authors:  Nicolas Bruffaerts; Marta Romano; Olivier Denis; Fabienne Jurion; Kris Huygen
Journal:  Vaccines (Basel)       Date:  2014-03-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.